Resveratrol as well as caloric restriction were shown to extend lifespan in some model organisms and may possibly delay onset of ageing-related diseases in humans. Yet, resveratrol supplementation does not always extend lifespan of animal models or improve health status of humans. Because of interindividual differences in human microbiota, resveratrol metabolite production in the gut differs. While some individuals produce lunularin and dihydroresveratrol in their gut, others produce dihydroresveratrol only. Therefore, we addressed the question whether these metabolites differ in their biological impact on ageing and intraperitoneally injected 13-month-old C57BL/6JRj mice on an ad-libitum (AL) HFD with resveratrol, dihydroresveratrol or lunularin (24 mg/kg bodyweight; 3 times/ week). Compared to mice injected with vehicle (AL-control), resveratrol and dihydroresveratrol did not change bodyweight and had no impact on insulin or glucose levels while lunularin slightly reduced feed intake and bodyweight gain. CR-mice showed lowered cholesterol, insulin and leptin levels, elevated adiponectin and phosphorylated AMpK levels in liver as well as increased transcription of Pck1 and Pgc1α when compared to the AL-control. In contrast, injections with the test substances did not change these parameters. We therefore conclude that in our model, resveratrol, lunularin and dihydroresveratrol did not act as CR mimetics.
In 2016, the EFSA concluded that resveratrol supplements up to 150 mg/day were safe for human use 27 . Thus, we chose a dose of approximately 10 mg resveratrol (or equimolar bioacatives)/day *kg mouse. Injecting the mice three times a week, this meant 24 mg/kg bodyweight. While dose scaling according to bodyweight would equal around 700 mg resveratrol/day for a 70 kg human, clearance ratios for xenobiotics were shown to rise with decreasing bodyweights. Applying allometric principles based on animal to human comparisons of total clearance rates, doses for humans that are extrapolated from mouse studies would be 5-10 lower than expected from mere conversion according to bodyweight 39 . Therefore, the dose applied to our mice would be comparable to 75-150 mg resveratrol per day in humans.
Results
Resveratrol and its metabolites are found in mouse liver. Resveratrol and the microbial metabolites dihydroresveratrol and lunularin were quantified in mouse liver samples by using a UHPLC-MS/MS method that meets the validation criteria of the FDA. In addition, 2 quality control samples (500 pmol/g liver analyte level) were measured together with the study samples to ensure proper analysis. The accuracies of these quality control samples were 99% and 100% for resveratrol, 97% and 99% for dihydroresveratrol and 113% and 111% for lunularin.
In the livers of the AL-control and CR-control neither resveratrol, nor dihydroresveratrol or lunularin were detected. In the resveratrol group only 5 out of 9 liver samples exhibited measurable, but low resveratrol levels (6.9 ± 4.0 pmol/g liver (mean ± SEM)), whereas dihydroresveratrol was present at significantly higher levels (230.0 ± 84.6 pmol/g liver (mean ± SEM)) in all these samples except one. This interesting finding indicates that resveratrol was efficiently metabolized to dihydroresveratrol in resveratrol-injected mice.
In mice receiving dihydroresveratrol, neither resveratrol nor lunularin was detected in the liver samples, whereas dihydroresveratrol was detectable in all samples from the dihydroresveratrol group with a mean level of 112.2 ± 30.0 pmol/g liver (mean ± SEM). Lunularin was only detectable in the lunularin group (28.8 ± 7.1 pmol/g liver (mean ± SEM)) but not in the groups receiving resveratrol or dihydroresveratrol.
Mean feed intake and bodyweight of resveratrol injected mice does not differ from AL-control mice. Feed intake was checked daily and weight weekly. While i.p. injections with resveratrol or dihydroresveratrol did not lower feed intake (3.00 ± 0.05 g and 3.01 ± 0.10 g, respectively) injecting lunularin slightly lowered feed intake compared to PEG/saline-injected mice (2.81 ± 0.1 g, p = 0.048 Dunnet AL-control, Supplemental Data X1). This slightly lower feed intake could explain the lower than AL-control body weight of lunularin mice at the end of the trial. A regression analysis of weekly mouse bodyweights showed that the difference in weight development between lunularin and AL-control mice was highly significant (p < 0.001). Resveratrol-injected and dihydroresveratrol-injected mice did not differ from AL-control mice (p = 0.147 and 0.764, respectively, Fig. 2 ). We excluded the CR mice from the statistical analysis of feed uptake and bodyweight.
CR but not resveratrol-injected mice have lower glucose and insulin levels in plasma than control mice on a high fat diet. Insulin sensitivity was monitored by oral glucose tolerance tests at the beginning, halfway through and at the end of the study. Analyses of the blood collected 30 minutes after applying a glucose bolus via gavage (2 g/kg mouse) showed that injections with resveratrol had not changed glucose or insulin levels compared to the controls. However, mice on CR showed improved insulin sensitivity as measured by glucose and insulin levels. Interestingly, after 8 weeks of injections with lunularin, glucose levels were slightly lower than in the controls (p = 0.03, Fig. 3 ).
CR but not resveratrol-injected mice had lower cholesterol and leptin plasma levels than control mice on a high fat diet. As expected, CR-feeding lowered leptin and total cholesterol levels compared to AL fed controls. In contrast, adiponectin was elevated by CR while triglyceride levels seemed unaffected ( Fig. 3c ). However, neither resveratrol nor its gut microbiota metabolites dihydroresveratrol or lunularin affected the hormones or lipids measured.
Transcription of genes involved in Sirt1-signalling and glucose metabolism in mouse liver was affected by CR but not by i.p. administered resveratrol. Pgc1-α mRNA, which is up-regulated under caloric restriction and may contribute to the life-prolonging effect of lowered calorie intake 3 , was elevated in our CR mice when compared to the controls. Since SIRT1 was shown to activate PGC-1α 7 and resveratrol was shown to activate SIRT1 and PGC-1α 15 , we also measured Sirt1 expression. While CR increased transcription, resveratrol did not significantly change Sirt1 mRNA levels in the liver. Interestingly, lunularin also shows a smaller than CR but significant increase in Sirt1 expression. Gluconeogenesis as measured by Pck1 expression appeared as not being influenced by resveratrol or resveratrol metabolite injections but by CR ( Fig. 4 ).
Transcription of longevity-associated Foxo3, cytokine Tnfα or Nrf2 target gene Hmox1 was not affected by i.p. administered resveratrol. NRF2 target gene Hmox1 was slightly induced by CR as well as by dihydroresveratrol and lunularin injections. However, resveratrol did not activate Hmox1 expression. mRNA levels of the transcription factor Foxo3 did not appear to be affected by any of the bioactives injected. Similarly, Tnfα expression appeared unchanged within the groups of our trial ( Fig. 4 ).
While AMPK is induced by CR, resveratrol and its metabolites do not lead to elevated levels of phosphorylated AMpK in mouse liver. In-vitro studies have shown that resveratrol can activate AMPK and lead to its phosphorylation 13 and, in accordance with Miller, et al. 5 , our mice on a CR diet showed elevated phospho-AMPK levels in liver. In contrast, in our mice injected with resveratrol, dihydroresveratrol or lunularin, we could not observe a rise of phosphorylated AMPK levels ( Fig. 5a ).
injected with resveratrol, MUP levels were not significantly lowered compared to the control ( Fig. 5b , left blot) and dihydroresveratrol-and lunularin-injected mice showed very similar MUP bands compared to resveratrol-injected mice ( Fig. 5b , right blot). In contrast, in CR mice, MUP levels were approximately 30% of ad-libitum fed mice. The MUP antibody used did not distinguish between different MUP isoforms.
Injections with resveratrol do not affect glucose transport in mouse ileum. To examine whether CR or resveratrol treatment affects the intestinal active glucose transport, the ileum of the animals was mounted in Ussing chambers. As shown in Fig. 6 , the glucose-induced I SC determined for the ilea of the CR and resveratrol groups were not significantly different when compared to that of the controls.
Materials and Methods
Mice, diet and intraperitoneal injections. Eleven-month-old C57BL/6Rj mice were purchased from Janvier Labs, Saint-Berthevin, France and kept on a high fat, high sugar purified diet (18.7% protein, 21.1% fat, 13.4% starch, 32.9% sugar, 2.1 mg/kg cholesterol, Ssniff, Soest, Germany). The mice were housed individually in macrolon cages (type 3) in 55% relative humidity, 21-25 °C and with a 12 h light/dark cycle at the Food Science Institute at the University of Kiel. Mice were weighed weekly and fed daily. After a 6-week ad-libitum adaptation phase, the experiment began by dividing the mice into 5 groups with 10 mice each. Then, the calorically restricted group was fed 5% less than what the control group fed every 3 days until reaching −40% restriction. When CR had reached 40%, injections started. Resveratrol, dihydroresveratrol and lunularin were dissolved in PEG400 (Sigma-Aldrich Taufkirchen, Germany), at concentrations equimolar to 30 mg resveratrol/mL. This stock was diluted with saline (Braun, Melsungen, Germany) until reaching a PEG concentration of 20% v/v and injected at 24 mg resveratrol or equimolar amounts of dihydroresveratrol or lunularin/kg bodyweight. The control and CR mice were injected with 20% PEG400 in saline. Because of animal welfare laws, if individual CR mice lost more than 20% of their weight at the beginning of the experiment, they were fed up to 70% of what the AL controls consumed.
At the beginning, halfway through the experiment and prior to sampling the body composition of the mice was measured in a Bruker Minispec LF (Billerica, United States). Per experimental group, 8-10 mice were sacrificed at the end of the experiment. We lost 2 mice each in the control and the CR group and 1 mouse in the containing saline (CON). CR -injections with vehicle/saline and 40% CR. Leptin and cholesterol levels in CR mice were significantly lower and adiponectin was significantly higher in CR mice than in CON mice. Plasma levels of leptin, adiponectin, cholesterol or triglycerides in CON mice injected did not differ statistically from mice injected with resveratrol, dihydroresveratrol or lunularin. ***p < 0.001, *p < 0.05, linear model, Dunnett CON (AL-control), n ≥ 8, except insulin measurements (n = 5-10).
www.nature.com/scientificreports www.nature.com/scientificreports/ resveratrol group. Experimental procedures were carried out in accordance with German laws on animal protection (TierSchG §7-9). The experiment (V 242-27717/2016 (46-4/16)) was approved by the MELUR (state government of Schleswig-Holstein, Germany). synthesis of resveratrol metabolites. Resveratrol for dihydroresveratrol synthesis and i.p. injections was purchased from Carl Roth (Karlsruhe, Germany). Dihydroresveratrol for i.p. injections was synthesized according to Faragher, et al. 40 . Lunularin (chemical purity >97%, determined by NMR) for i.p. injections and the analysis of resveratrol and its metabolites in mouse liver samples at the MRI Karlsruhe (Germany) was prepared as described previously in a modular synthesis 41 .
Analysis of resveratrol and metabolites in mouse liver samples. The UHPLC-MS/MS analysis and the sample preparation for these analyses took place at the MRI, Karlsruhe, Germany. For a more exhaustive description, see Supplemental Methods. Mouse livers were homogenized with a ball mill (MM400; Retsch, Haan, Germany) spiked with internal standards and processed for UHPLC-MS/MS analyses on an QTrap 5500 mass spectrometer (AB Sciex, Darmstadt, Germany).The spectrometer was equipped with a Nexera LC www.nature.com/scientificreports www.nature.com/scientificreports/ system (Shimadzu, Duisburg, Germany) which consisted of a controller (CBM-20A), a degasser (DGU-20A5), two pumps (LC-30AD), an autosampler (SIL-30AC), a column oven (CTO-20AC) and a DAD (SPD-M20A). Separation of the analytes was achieved on a Waters Acquity HSS T3 (2.1 mm × 100 mm, 1.8 µm particle size) equipped with a pre-column (Waters Acquity HSS T3, 2.1 mm × 5 mm, 1.8 µm particle size) and a pre-in-line filter (Phenomenex Krudkatcher, 0.5 µm). The mobile phase consisted of an aqueous 25 mM ammonium formate buffer with 0.1% (v/v) formic acid and acetonitrile. The turbo spray ESI source of the MS was operated in the negative mode.
Analysis of UHPLC-MS/MS data was performed with the MultiQuant 2.1.1 software (ABSciex, Darmstadt, Germany). To obtain the calibration curves, the ratios of the analyte peak areas to the internal standard peak area were calculated and plotted against the analyte level. A best fit line was obtained by linear regression using a weighting of 1/x 2 . The method was validated based on FDA criteria.
For calculation of means and SEMs, values below the limit of detection (LOD) were set as 0.01 pmol/g liver and values between limit of quantitation (LOQ) and LOD were set as LOQ/2. n.d., not detected, values <LOD: resveratrol <2.0 pmol/g liver, dihydroresveratrol <2.3 pmol/g liver, lunularin <9.7 pmol/g liver. Blood parameters. Insulin levels were measured in serum using the Ultra Sensitive Mouse Insulin kit from Crystal Chem (Zaandam, Netherlands), leptin and adiponectin levels were measured in plasma using the mouse ELISA kits from R&D Systems (Abingdon, UK), total cholesterol was measured using the fluorimetric assay kit from Cayman Chemicals via Biomol (Hamburg, Germany) and triglycerides were measured using the Fluitest TG kit from Analyticon (Lichtenfels, Germany) all according the manufacturer's instructions. Glucose levels in whole blood were measured using the Free Style glucometer from Abbott (Abbott Park, Illinois, United States).
oral glucose tolerance test. At the beginning, halfway through the experiment and prior to sampling, mice were fasted for 5 hours before receiving 2 g glucose/kg body weight via gavage. Thirty minutes later, blood was collected by puncturing the facial vein and glucose and insulin levels were determined. Glucose was purchased from Carl Roth (Karlsruhe, Germany) and dissolved at 0.5 g/mL in autoclaved tap water (Kiel, Germany).
mRNA polymerase chain reaction. Liver total RNA was isolated using peqGold Trifast ® (Peqlab, Erlangen, Germany). RNA concentration and purity were determined by measuring the absorbance at 230, 260 and 280 nm with a NanoDrop 2000 TM (Thermo Fisher, Waltham, USA). RNA aliquots were stored at −80 °C until PCR analysis. One-step quantitative reverse transcriptase PCR was carried out with the SensiMix ™ SYBR No-ROX one step kit (Bioline, Luckenwalde, Germany) and with SybrGreen detection using the Rotorgene 6000 cycler (Corbett Life Science, Sydney, Australia). Relative mRNA levels of target genes were normalised to Gapdh and Actb gene expression and related to the AL-control. Mean value of expression in the AL-control group was set to an arbitrary unit of 1. All data are represented as means +/− SEM (n ≥ 8). See primers in Table 1 .
Western blotting. Cytosolic liver extracts were prepared by homogenizing fresh tissue in 10 mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM DTT, 0.1% Nonidet-P40, protease inhibitor cocktail and PhosSTOP TM (all Sigma-Aldrich), leaving it on ice for 30 min with occasional vortexing before centrifuging at 4000×g and 4 °C for 5 min. Supernatant protein concentrations were determined with the BCA assay (Thermo Fisher Scientific, Schwerte, Germany). The samples were mixed with loading buffer, denatured at 95 °C for 5 min and separated on TGX Stain-Free Precast gradient gels (Biorad, Munich, Germany) and blotted onto a PVDF membrane. The membrane was blocked with 5% skim milk dissolved in TBS with 0.05% Tween-20 and probed with a primary antibody overnight (MUP antibody sc-21856, Santa Cruz Biotechnology Inc., Heidelberg, Germany; p-AMPK antibody CS-2523, Cell Signalling, Leiden, The Netherlands; Actin antibody ab3280, Abcam, Cambridge, UK) followed by a secondary antibody (anti-goat sc-2354: Santa Cruz Biotechnology Inc., Heidelberg, Germany, anti-mouse 170-5047; anti-rabbit 170-5046: Biorad). The bands were visualized with ECL reagent (Thermo Fisher Scientific) in a ChemiDoc XRS system (BioRad). www.nature.com/scientificreports www.nature.com/scientificreports/ (Acquire & Analyze Data) acquisition software (Physiological Instruments). Transepithelial resistance and ISC were allowed to stabilize for approximately 20 min. After that, 10 mM glucose were added apically to stimulate Na + -coupled glucose transport; 10 mM mannitol were given basolaterally. The glucose-stimulated ISC reached a stable plateau within 10 min. The ΔISC value that indicates intestinal SGLT-1 dependent glucose transport was calculated by the difference: ISC (with apical glucose) -ISC (without apical glucose). statistics. The statistical software R 42 was used to evaluate the data. For a more exhaustive description, see Supplemental Methods. Appropiate models were defined 43, 44 . Based on graphical residual analyses the data was assumed to be approximately normally distributed. While for the blood parameters, feed intake and normalized mRNA levels an analysis of variances (ANOVA) was conducted, an analysis of covariances (ANCOVA) was conducted for the weight development 45, 46 . These analyses were followed by multiple contrast tests (Dunnett) 47 .
Ussing chamber measurements.

Discussion
Our study design included daily control of feed uptake and a controlled application of resveratrol and its metabolites. Moreover, we had AL fed mice as a negative control group and CR fed mice as a positive control group. Although we applied the substances intraperitoneally, we found the gut microbiota metabolite of resveratrol, dihydroresveratrol, in our resveratrol group.
While it is possible that we would have had more statistically significant results using a higher number of animals, we observed that many parameters described as being affected by resveratrol hardly changed or even (not significantly) tended to be further away from CR-control values than from AL-control values (for example, average bodyweight gain in resveratrol-injected mice was 3.3 g and 3.0 g in the AL-controls (Supplemental Data X-1)). Therefore, we do not think our non-significant results are a problem of statistical power. However, we did not carry out lifespan studies and only used one dose of resveratrol and its metabolites. Furthermore, our inbred strain used (C57BL/6Rj) might be less sensitive to resveratrol supplementation than more genetically heterogenous mice 48 or other mouse genotypes 14 .
Interestingly, there is evidence in rodents and lower model organisms that resveratrol may not always extend lifespan or benefit health 28, 49 . Negative results have also been reported for human trials supplementing resveratrol 31, 50 .
Our CR mice showed a clear CR phenotype (lowered body weight, lowered glucose, insulin, leptin, cholesterol and elevated adiponectin) 11, 51 and we found changes in molecular targets typically affected by restricting feed intake such as MUP, pAMPK protein and Pgc-1α mRNA levels 5, 11 . In contrast, injections with resveratrol or dihydroresveratrol did not affect bodyweight or the blood parameters measured compared to the control. Consistently, we did not observe differences in protein or mRNA levels measured in resveratrol-or dihydroresveratrol-injected mice.
Interestingly, injections with lunularin led to slightly lowered bodyweight and glucose levels in the mice. However, the mice fed less when injected with lunularin and this may be an indirect CR effect induced by lunularin lowering feed intake. This could also explain changes in blood parameters and mRNA expression that show the same tendency as CR and are significant for Sirt1 in lunularin mice (Fig. 5 ).
While we found resveratrol and lunularin only in the mice that had been injected with the corresponding substance, we found dihydroresveratrol in resveratrol-injected mice. Furthermore, we found rather high inter individual variability in resveratrol and -metabolite levels. Resveratrol, dihydroresveratrol and lunularin liver levels at sampling depend on how fast the polyphenols were taken up after injection and on the rate of excretion. The rate of excretion depends largely on phase II metabolism that is known for large inter-individual variability 52 . Phenolic levels after oral administration in inbred mice showed standard deviations that were larger than the means 53 . In our mice, we find the highest variation in the dihydroresveratrol levels of resveratrol-injected mice. Here, we would expect to have even higher variability since these levels do not only depend on uptake and excretion but also on metabolization of resveratrol to dihydroresveratrol.
As far as we are concerned, murine metabolic enzymes that can reduce double bonds have not been identified. Therefore, finding dihydroresveratrol in resveratrol-injected mice points to the notion that resveratrol could be excreted into the gut, where its double bond is reduced by microbiota and, as a consequence, dihydroresveratrol is (re)absorbed. In line with this hypothesis, enterohepatic recirculation of resveratrol has been observed in rats before 54 . Alternatively, a liver reductase with affinity to resveratrol could have also produced dihydroresveratrol. However, further studies to clarify the origin of the dihydroresveratrol in resveratrol-injected mice were beyond the scope of this study.
The finding that resveratrol injections had no impact on insulin and glucose levels (and other parameters) stands in contrast to earlier findings 13, 48 . Similar to Baur, et al. 13 , we used male ca. 1-year-old C57BL/6 mice on high fat diet. Conversely, we injected rather than fed resveratrol as part of the diet. Because of the different administration routes, resveratrol uptake doses are difficult to compare with each other. However, with 0.4 g resveratrol/kg feed and 72 mg resveratrol/(kg bodyweight week), assuming a feed intake per mouse per day of 3.5 g feed and a 35 g mouse, this would equal a daily intake per mouse of 1.4 mg via diet versus 0.36 mg i.p. Of interest, related to bodyweight, 1.4 mg resveratrol/35 g mouse would be 2.8 g of resveratrol for a human subject of 70 kg. However, interspecies extrapolation for micronutrient requirements or toxicological risk assessment is often flawed when merely using bodyweights. Applying allometric principles and taking different caloric demands of mice and humans into account, it is possible that, related to bodyweight, humans need an approximately 5-10-fold lower dose of resveratrol than mice for an effect 39, 55 . Intake of resveratrol without further supplementation has been estimated to average 80-900 µg/day 56, 57 . Yet, administering higher doses of resveratrol and its metabolites to our mice might have had an impact on insulin signalling. Furthermore, our diet had around 40% calories from fat while Baur and colleagues fed 60% calories from fat. In addition, our trial was shorter than the lifespan trial by Baur, et al. 13 . While resveratrol has been shown to affect ageing-related parameters after short term feed supplementation, in mouse strains other than C57BL/6, glucose tolerance was only slightly affected by resveratrol www.nature.com/scientificreports www.nature.com/scientificreports/ feed supplementation for 6 or 15 weeks 14 or not at all 48 . Although we assume that at least part of the resveratrol we applied i.p. located to the gut because of enterohepatic circulation 54 , injecting rather than feeding resveratrol might have diminished effects of resveratrol on the microbiota or the intestinal sodium-dependent-glucose transport. When fed, resveratrol concentration in the gut is quite high and exposure is likely increased because it may re-enter the gut after uptake 54 . Here, it may interfere with glucose and alanine uptake via the SGLT1 58 without affecting intestinal SGLT1 expression 59 . However, glucose uptake by SGLT1 was shown to be largely influenced by postranslational modification of the transporter and less by mRNA levels 60, 61 . We did not observe differences in glucose uptake between intestines from resveratrol-injected mice and vehicle-injected mice (Fig. 6 ). Moreover, intestinal glucose transport of CR and CON mice did not differ significantly, possibly due to rather high inter individual deviations. However, higher glucose transport in the intestines of mice on long-term CR has been reported before 62 . Thus, it is possible that some type of adaptation leads to increased glucose transport and thereby, in part, compensates for low glucose feed intake that occurs in mice with limited nutrient supply.
In our settings, resveratrol did not alter transcription of genes previously described as responding to CR or the stilbene itself. This included transcription factors and their target genes as well as genes involved in metabolism (Pck1, Pgc-1α, Sirt1, Hmox1, Foxo3 and Tnfα) .
A reason for our contradicting data could be the timepoint we terminated the experiment. In a study by Fusser, et al. 16 , Hmox1 expression was only elevated after short term application (7 days) of resveratrol and not after 6 months. However, the microbial metabolites lunularin and dihydroresvertrol activated Hmox1 in our settings but resveratrol did not (p = 0.8). This is interesting because we find dihydroresveratrol also in the liver of resveratrol-injected mice.
Tnfα downregulation in mice liver was observed in 24 month old mice after 6 months of supplementation 20 while our mice were almost 10 months younger. Although resveratrol was shown to activate the SIRT1 homologue SIR2 in yeast 1 , the stilbene may not act via PGC-1α 14 or even activate mitochondrial biogenesis in rodents 63 .
Our finding that injections with resveratrol did not affect AMPK phosphorylation in mouse liver (Fig. 5a ) is somewhat interesting since resveratrol has been described as activating AMPK and its action as being dependent on AMPK 6 . However, in the study cited, resveratrol was supplemented to the diet and the mice were younger than ours. Furthermore, Um and colleagues focussed on skeletal muscle and, also in contrast to our findings (Fig. 2b,c) , found lowered fat mass in resveratrol-treated mice.
In liver homogenates from mice fed CR, MUP levels were considerably lower than in ad-libitum fed mice. There are various, highly polymorphic MUP isoforms. MUPs bind to pheromones and are excreted into urine where the pheromones are released from the MUPs in urine marks 64 . MUPs are central for interindividual recognition and reproduction in mice 65 . MUP expression is affected by diet and MUP1 may counteract insulin resistance and inhibit expression of gluconeogenic genes 66 . On one hand, mice on CR showed lowered MUP1 and MUP5 levels 6, 12 , on the other hand, MUP levels were also reduced by high fat diet 10 For mice on a high fat diet supplemented with resveratrol, up-regulation of MUP 1 and MUP 3 mRNA levels in liver has been reported 13 . While we could not distinguish between different MUP isoforms measuring protein levels via Western blot, we found reduced MUP in mice that fed 60% of a high fat diet compared to the AL-control. Injecting resveratrol (or resveratrol metabolites) did not affect MUP levels compared to animals injected with vehicle and saline (Fig. 5b) .
Taken together, injecting C57BL/6 mice on a high fat diet with resveratrol or dihydroresveratrol, in contrast to CR-feeding, did not affect body weight, glucose, insulin, adiponectin, leptin or cholesterol blood levels, did not lower hepatic Pck1, Pgc1α or Sirt1 mRNA levels and did not change phosphorylated AMPK or MUP protein levels in liver. For reasons, of which identifying the underlying mechanisms was beyond the scope of our study, lunularin lowered feed intake and, possibly as a consequence, body weight. Decreased feed intake (and therefore not lunularin itself) is likely to have caused lowered glucose and Sirt1 mRNA levels. However, we cannot rule out that lunularin activated molecular targets leading to these outcomes.
By comparing our negative data for resveratrol as CRM with literature data from model organisms and human trials, we conclude that resveratrol may only exert its putative health effects under certain circumstances. Therefore, caution should be warranted when promoting resveratrol as caloric restriction mimetic.
